A late-stage multi-dimensional intervention rescues lethal viral pneumonia in an aged hamster model.

A late-stage multi-dimensional intervention rescues lethal viral pneumonia in an aged hamster model.

Publication date: Sep 02, 2026

Severe pneumonia caused by respiratory virus infection is one of the main threats to the lifespan of the aged population and physiological aging fundamentally drives poor disease outcomes in respiratory viral infections, necessitating investigation of the underlying mechanisms and the development of effective countermeasures. Pulmonary transcriptomic profiling reveals that diffuse cell death, inadequate antiviral responses, myeloid-driven excessive inflammation and immune-thrombosis dictate the pulmonary microenvironment are typical molecular pathology characteristics of the SARS-CoV-2-infected aged hamsters rather than the adult controls. The elevated pathological baseline and dysregulated immune responses are demonstrated as the key host factors of lethal viral pneumonia in the aged hamsters. Meanwhile, SARS-CoV-2 infection in the adult hamsters usually resulted in an aged-like pulmonary transcriptomic signature, suggesting a potential link among aging, dysregulated immune responses and severe illness. To reverse the progression of lethal severe pneumonia in the aged hamsters, we initiated a multidimensional combination therapy of dexamethasone, heparin and the broad-spectrum viral decoy CoVR-MV at three days after infection. Although single- and dual-drug therapies were insufficient to achieve functional cure, the three-drug combination therapy resulted in a potent reduction of high mortality, body weight loss, viral load, lung pathology and cytokine storm through the synergism of immunoregulatory, anticoagulant and antiviral effects, effectively intercepting the multifaceted pathogenic network. This study highlights physiological aging as a core driver of critical COVID-19 pathogenesis and provides valuable clues for the rational design of multi-drug and multi-target therapies against respiratory viral infections and lethal severe pneumonia in the elderly population.

Open Access PDF

Concepts Keywords
Biomed Aging
Hamsters Aging
Lethal Animals
Pneumonia Antiviral Agents
Stage Antiviral Agents
Combined therapy
Coronavirus Infections
COVID-19
Cricetinae
Dexamethasone
Dexamethasone
Disease enhancement
Disease Models, Animal
Drug Therapy, Combination
Fatal severe pneumonia
Heparin
Heparin
Lung
Male
Mesocricetus
Pneumonia, Viral
Respiratory virus infections
SARS-CoV-2
SARS-CoV-2
Viral Load

Semantics

Type Source Name
disease MESH viral pneumonia
disease MESH pneumonia
disease MESH virus infection
disease MESH inflammation
disease MESH thrombosis
disease MESH SARS-CoV-2 infection
pathway REACTOME SARS-CoV-2 Infection
drug DRUGBANK Dexamethasone
drug DRUGBANK Heparin
disease MESH infection
disease MESH weight loss
disease MESH cytokine storm
pathway REACTOME Reproduction
disease MESH included
disease MESH death
disease MESH infectious diseases
disease MESH RSV infection
disease MESH fever
disease MESH cough
disease MESH dis
disease MESH delirium
disease MESH lethargy
disease MESH emergency
drug DRUGBANK Trestolone
drug DRUGBANK Anakinra
disease MESH premature aging
disease MESH reinfection
drug DRUGBANK Dextromethorphan
disease MESH lung injury
disease MESH strains
disease MESH body weight
disease MESH ham
drug DRUGBANK Pidolic Acid
disease MESH PCA
pathway REACTOME Apoptosis
pathway REACTOME Metabolism
disease MESH hypoxia
pathway KEGG Insulin secretion
disease MESH andd
disease MESH Coronavirus Infections
disease MESH Disease Models Animal

Original Article

(Visited 20 times, 1 visits today)

Leave a Comment

Your email address will not be published. Required fields are marked *